Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2025-01-21 Regulatory Filings
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
NANOBIOTIX annonce le traitement du premier patient dans une nouvelle étude randomisée de phase 2 évaluant JNJ-1900 (NBTXR3) chez des patients atteints d’un cancer du poumon non à petites cellules de
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a clinical trial update: the first patient treated in a Phase 2 study (CONVERGE) for NBTXR3. It discusses ongoing clinical development, partnerships (Janssen), and references future regulatory filings (Fast Track designation, Phase 3 study NANORAY-312). Crucially, it contains a standard 'Avertissement' (Disclaimer) section that explicitly references the company's 'Form 20-F' filed with the SEC and other periodic reports. This structure—a brief announcement of operational/clinical progress, often issued outside of standard SEC filing deadlines—is characteristic of a general press release or regulatory announcement. Since it is not a full financial report (10-K, IR) or a specific dividend/insider trade notice, and it serves as a general update to the market, it best fits the Regulatory Filings (RNS) category, which acts as a catch-all for important, non-standardized announcements, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is purely clinical/operational news. Given the nature of clinical trial milestones being announced via press release, RNS is the most appropriate classification.
2025-01-21 French
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Regulatory Filings Classification · 100% confidence The document is explicitly titled "# *PRESS RELEASE*" and announces a specific corporate event: dosing the first patient in a new clinical study (CONVERGE study) for their product JNJ-1900 (NBTXR3). This type of announcement, detailing clinical trial progress, partnerships (with Janssen/J&J), and providing company updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing operational/clinical progress rather than a formal financial statement (like 10-K or IR) or a transcript (CT), it fits best under the 'Earnings Release' category if it contains key operational highlights, or 'Regulatory Filing' if it's purely informational. Given the structure and content (clinical trial update, CEO quote, product description, disclaimer), it functions as a major operational update, which often accompanies or substitutes for a formal Earnings Release in biotech/pharma sectors when reporting milestones. However, it is not a summary of quarterly financial results (ER). It is a specific announcement about a clinical milestone. Since it is a formal press release announcing a significant operational/clinical event, and it is not a report itself, it falls under the general category for significant, non-standard announcements. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing clinical trial progress that doesn't fit ER, AR, or CT, although it contains elements often found in an ER (CEO quote, company overview). Upon review, this is a clinical trial update press release. While ER is for financial results, RNS is the general regulatory announcement category. Since it is a formal press release announcing a major operational milestone, RNS is the safest classification, as it is not a financial report, transcript, or specific management/director filing.
2025-01-21 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'AMF) and provides a table detailing the total number of shares and voting rights as of December 31, 2024. This content directly relates to reporting changes in share capital and voting rights, which falls under the category of Major Shareholding Notification (MRQ) or potentially a specific regulatory filing. However, the core content is a mandatory monthly disclosure about the total share capital and voting rights, which is a specific type of regulatory disclosure. Given the options, this type of regular capital structure update is most closely aligned with 'Major Shareholding Notification' (MRQ) as it deals with the composition of the capital base that determines ownership thresholds, or potentially 'Regulatory Filings' (RNS) if MRQ is strictly for crossing thresholds. Since it is a regular, mandatory disclosure about the total number of shares/votes, and not a specific transaction (POS) or a general announcement (RNS), MRQ is the most appropriate fit among the specific options, as it concerns the underlying structure relevant to major holdings. However, looking closely at the definitions, MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)'. This document reports the *total* count, which is the basis for calculating thresholds, but doesn't necessarily report a *change* in a major shareholder's holding crossing a threshold. The closest fit for mandatory periodic disclosure about share capital structure is often grouped with filings related to ownership changes. Given the explicit focus on 'Nombre total d'actions' and 'Nombre total de droits de vote' as required by AMF rules, this is a specific regulatory disclosure. If a more precise code for 'Total Voting Rights Disclosure' existed, it would be used. In the absence of that, and considering it's a mandatory regulatory update concerning capital structure, RNS (Regulatory Filings - fallback) is a strong candidate, but MRQ relates directly to the data presented (voting rights/shares). Since it is a periodic report on the total capital base, and not a general announcement, I will classify it as MRQ as it provides the necessary data for tracking major holdings, or RNS if it's considered a general regulatory update. Given the highly specific nature of the data (total shares/votes), and the lack of a dedicated 'Share Capital Disclosure' code, RNS is the safest fallback for a mandatory regulatory report that doesn't fit the other specific categories perfectly. Re-evaluating: This is a mandatory monthly disclosure of the total share capital and voting rights, often required by exchanges/regulators. This is a very specific type of regulatory filing. If it's not an ER, IR, or 10-K, RNS is the general regulatory filing bucket. I will select RNS as the most appropriate general regulatory filing category for this mandatory monthly disclosure.
2025-01-09 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release dated January 9, 2025, titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY." It explicitly states the total number of shares outstanding and the total number of voting rights (theoretical and exercisable) as of December 31, 2024, referencing French Commercial Code and AMF regulations. This type of periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory requirement. Among the provided definitions, this content most closely aligns with a notification related to capital structure or a general regulatory update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a dividend announcement (DIV), and it specifically details the capital structure (shares outstanding and voting rights), it fits best under 'Share Issue/Capital Change' (SHA) or potentially 'Regulatory Filings' (RNS) as a fallback. However, because the core content is the calculation and announcement of the total number of voting rights and shares, which directly impacts capital structure reporting, SHA is the most precise fit, although DVA (Declaration of Voting Results) is related, DVA usually refers to the *results* of a vote, not the *basis* for voting rights calculation. Given the focus on the total number of shares and voting rights, SHA is the most appropriate classification for a capital structure disclosure of this nature, even if it's not a new issuance.
2025-01-09 English
NANOBIOTIX présentera sa vision pour révolutionner la conception et le développement de médicaments à travers sa prochaine plateforme nanothérapeutique le 19 décembre 2024
Investor Presentation Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a future virtual event scheduled for December 19, 2024, where the company will present its vision and platform. It details the title, date, time, format, and registration link for this event. This type of announcement, which publicizes an upcoming investor/analyst presentation or call, fits best under the category of an Investor Presentation (IP) announcement or, more generally, a Report Publication Announcement (RPA) if it were announcing the release of a formal report. However, since the core content is about an upcoming presentation/event where strategy and technology will be discussed, and it is structured as a formal press release detailing the event logistics, it is most accurately classified as an announcement related to an Investor Presentation (IP). Given the options, and since it is not the presentation itself but the announcement of the event, RPA might be considered, but IP is more specific to the content being presented (technology, strategy). Since the document is a press release announcing a future event where an Investor Presentation will occur, and it is not a standard regulatory filing like 10-K or ER, it is a communication aimed at investors about future content. If the event itself were the presentation, IP would be perfect. As an announcement of an event that *is* essentially an investor presentation, IP is the closest fit for the subject matter, although RPA is also plausible if we strictly follow the 'announcement' rule. Given the detailed agenda focusing on technology and strategy, I will classify it as an Investor Presentation (IP) announcement, as it directly relates to the content being shared at the event.
2024-12-17 French
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Regulatory Filings Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces a future virtual event where the company will introduce its vision for a new nanotherapeutic platform. It provides details on the date, time, speakers, and registration link for this event. This type of announcement, which publicizes an upcoming investor/analyst presentation or call, is best classified as an Investor Presentation (IP) announcement or, more generally, a communication related to investor engagement. However, since the document itself is the announcement of the event, and not the transcript (CT) or the presentation slides (IP), and it is a general press release about a future strategic update, it fits best under the category of a general announcement or a precursor to an investor event. Given the options, and noting that it is a press release detailing an upcoming strategic/technology presentation, it is closely related to Investor Presentation (IP). However, if the event itself were to be classified, it would be IP. Since this is the announcement of the event, and it is not a standard regulatory filing like 10-K or ER, it is a general corporate communication. The closest fit among the specific options for an announcement about a future investor-focused presentation is often considered related to Investor Presentation (IP) or a general Regulatory Filing (RNS) if no better fit exists. Since the content is entirely focused on introducing a new platform to investors/analysts, classifying it as an Investor Presentation (IP) related document is appropriate, as it sets the stage for that information dissemination. It is not a Call Transcript (CT) because it is an announcement, not the transcript itself. It is not an Earnings Release (ER) as it concerns technology strategy, not financial results. I will classify it as Investor Presentation (IP) because the subject matter is the introduction of a new platform to investors.
2024-12-17 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.